Literature DB >> 11102894

Altered expression of HLA class I antigens in breast cancer: association with prognosis.

I Gudmundsdóttir1, J Gunnlaugur Jónasson, H Sigurdsson, K Olafsdóttir, L Tryggvadóttir, H M Ogmundsdóttir.   

Abstract

Loss of surface expression of class I major histocompatibility antigens is commonly observed in malignant tumors and has been considered one of the mechanisms for escape from cytotoxic T cells. However, natural killer cells kill cells lacking HLA class I antigens. In the present study, we characterized by immunohistochemistry the HLA class I expression of breast carcinomas from 187 patients with TNM stages I and II, diagnosed 1981-1984, using beta(2)-microglobulin as a marker and evaluated the effect on survival with a follow-up of up to 14 years. The largest group (48%) consisted of HLA class I-negative tumors (< or =10% of cells stained), mixed expression (>10% and <80% of cells stained) was seen in 36% and only 15% were classified as HLA class I-positive (> or=80% cells stained). No associations could be established with various clinicopathological parameters, such as tumor size, presence of lymph node metastases, histological grade, expression of hormone receptors, S phase and p53 mutations. There was no effect on recurrence-free survival in the whole group; but among node-negative patients (n = 86), those who had tumors with mixed HLA class I expression had a significantly higher probability of disease recurrence (OR = 3.42, p = 0.014) than patients with either HLA class I-positive or -negative tumors, particularly after more than 5 years. In node-positive patients who received adjuvant therapy, this phenotype was not associated with disease recurrence. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102894     DOI: 10.1002/1097-0215(20001120)89:6<500::aid-ijc6>3.0.co;2-#

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma.

Authors:  Alessandra Favole; Paolo Cascio; Fulvia Cerruti; Alessandra Sereno; Massimiliano Tursi; Alessandro Tomatis; Cristina Della Beffa; Soldano Ferrone; Enrico Bollo
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

Review 2.  The contribution of inherited factors to the clinicopathological features and behavior of breast cancer.

Authors:  W D Foulkes; J Rosenblatt; P O Chappuis
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

3.  Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines.

Authors:  H Pandha; A Rigg; J John; N Lemoine
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

4.  Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker.

Authors:  Ida Johansson; Cecilia Nilsson; Pontus Berglund; Martin Lauss; Markus Ringnér; Håkan Olsson; Lena Luts; Edith Sim; Sten Thorstensson; Marie-Louise Fjällskog; Ingrid Hedenfalk
Journal:  Breast Cancer Res       Date:  2012-02-14       Impact factor: 6.466

5.  High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis.

Authors:  Maria Benevolo; Marcella Mottolese; Elisa Tremante; Francesca Rollo; Maria Grazia Diodoro; Cristiana Ercolani; Isabella Sperduti; Elisa Lo Monaco; Maurizio Cosimelli; Patrizio Giacomini
Journal:  J Transl Med       Date:  2011-10-27       Impact factor: 5.531

6.  Rejection of immunogenic tumor clones is limited by clonal fraction.

Authors:  Ron S Gejman; Aaron Y Chang; Heather F Jones; Krysta DiKun; Abraham Ari Hakimi; Andrea Schietinger; David A Scheinberg
Journal:  Elife       Date:  2018-11-30       Impact factor: 8.140

7.  High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study.

Authors:  David Cantú de León; Delia Pérez-Montiel; Verónica Villavicencio; Alejandro García Carranca; Alejandro Mohar Betancourt; Victor Acuña-Alonzo; Alberto López-Tello; Gilberto Vargas-Alarcón; Rodrigo Barquera; Neng Yu; Edmond J Yunis; Julio Granados
Journal:  BMC Cancer       Date:  2009-02-05       Impact factor: 4.430

8.  Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells.

Authors:  G L Scheffer; M C de Jong; A Monks; M J Flens; C D Hose; M A Izquierdo; R H Shoemaker; R J Scheper
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

9.  Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer.

Authors:  Gisela Bevilacqua Rolfsen Ferreira da Silva; Tarsia Giabardo Alves Silva; Roberta Aparecida Duarte; Nicolino Lia Neto; Hélio Humberto Angotti Carrara; Eduardo Antônio Donadi; Maria Alice Guimarães Gonçalves; Edson Garcia Soares; Christiane Pienna Soares
Journal:  Int J Breast Cancer       Date:  2013-12-02

10.  NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells.

Authors:  Vincenzo Quagliariello; Michelino De Laurentiis; Stefania Cocco; Giuseppina Rea; Annamaria Bonelli; Antonietta Caronna; Maria Cristina Lombari; Gabriele Conforti; Massimiliano Berretta; Gerardo Botti; Nicola Maurea
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.